NCT00306618

Safety and Efficacy Study of Panzem NCD to Treat Glioblastoma

A Single-Center, Open-Label, Phase II, Safety, Pharmacokinetic and Efficacy of Panzem Nanocrystal Colloidal Dispersion Administered Orally to Patients With Recurrent Glioblastoma Multiforme

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 27 (actual)
• Sponsor: CASI Pharmaceuticals, Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This single-center, open-label, phase 2 study will evaluate the anti-tumor activity, as well as the safety and pharmacokinetics, of Panzem (2-methoxyestradiol, 2ME2) Nanocrystal Colloidal Dispersion (NCD) administered in patients with recurrent glioblastoma multiforme (GBM)

Conditions

• Recurrent Glioblastoma Multiforme

Interventions

Type	Name	Description
DRUG	Panzem Nanocrystal Colloidal Dispersion	Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing

Timeline

• Start date: 2006-01-01
• Primary completion: 2007-11-01
• Completion: 2008-12-01
• First posted: 2006-03-24
• Last updated: 2008-12-10

Locations

1 site across 1 country: United States